BioSpace News Archive

Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the BofA Securities 2023 Health Care Conference on Wednesday, May 10, 2023 , at 1:40 p.m. PDT.

Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has entered into a worldwide collaboration and license agreement with Cellular Biomedicine Group Inc. (CBMG) to develop, manufacture and commercialize next-generation chimeric antigen receptor (CAR) T-cell therapies for the treatment of B-cell malignancies.

Pathnostics today announced publication of data from the Company’s interim analysis for a prospective observational study evaluating Guidance® UTI in patients with complicated urinary tract infections (cUTIs) in the peer-reviewed journal Research and Reports in Urology.

D&D Pharmatech, Inc. (D&D), a clinical-stage biotechnology company focused on the development of disease-modifying drugs, today announced positive topline results from its Phase 1 clinical trial of DD01 in overweight/obese patients with type 2 diabetes (T2D) and non-alcoholic fatty liver disease (NAFLD).

Xeris Biopharma Holdings, Inc. today announced that the Company will release its first quarter 2023 financial results before the open of the U.S. financial markets on Tuesday, May 9, 2023.

Anavo Therapeutics announced today an EUR 8.5 million seed round extension, adding MRL Ventures Fund as a new investor. All existing investors, M Ventures, INKEF, Taiho Ventures, and Bioqube Ventures, participated in the extension, bringing the total seed round to EUR 28 million.

Syros Pharmaceuticals today announced the grant of restricted stock unit (RSU) awards for an aggregate of 17,800 shares of Syros common stock to two newly hired employees in connection with commencing employment with Syros.

ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, May 9, 2023 at 8:30 a.m. EDT to report financial results for the first quarter 2023 and provide business updates.

Rapid Dose Therapeutics Corp. (“ RDT ” or the “ Company ”) (CSE: DOSE) is pleased to announce that on May 1, 2023, staff of the Ontario Securities Commission (the “ OSC ”) granted a full revocation of the failure-to-file cease trade order (“ FFCTO ”) that was previously issued against the Company on August 26, 2022.

Can-Fite BioPharma Ltd. today announced that it discovered the mechanism of action (MOA) involved with the significant anti-cancer effect of Namodenoson in pancreatic carcinoma. Namodenoson de-regulates the Wnt signal transduction pathway, a key modulator of pancreatic carcinoma cell growth.